blank
blank

Ethics and regulatory guidance to address the challenges encountered in research on rare diseases in a multinational dimension: the experience of a European funded programme

1:1

blankpublication

This BMC Medical Ethics article examines ethics and regulatory guidance across EJP RD-funded rare disease research projects.

The article analyses 65 projects funded by the European Joint Programme for Rare Diseases (EJP RD) to identify ethics and regulatory issues encountered by researchers and to describe the guidance provided through the programme’s Ethics Follow-up process. Most projects addressed human participants and personal data, including genetic data, biospecimens, children and non-EU country involvement. The abstract reports that EJP RD guidance supported ethics compliance, while regulatory procedures were often overlooked, highlighting a need to strengthen regulatory awareness in rare disease research.

Acces this publication (pdf)
BMC Medical Ethics

Source

BMC Medical Ethics; publisher: BMC

You might also be interested in

Female scientist in protective gear using lab equipment for research.. Photo by ima Miroshnichenko via Pexels (CC0)

Biotech Act II: European Commission opens Call for Evidence on industrial biotechnology and biomanufacturing

The European Commission has opened a Call for Evidence on the upcoming Biotech Act II — with feedback open until 10 June 2026, inviting stakeholders to submit input that will help shape the initiative before a legislative proposal is prepared.
ERDERA First Policy Think Tank meeting

ERDERA Policy Think Tank meets in Paris to advance data and registry policy for rare diseases

Bringing together policy makers, researchers and data experts to align on how registry data can better support rare disease research and evidence‑based policy across Europe.
kitt_ks-lab-2107514_1920

Towards animal-free testing: virtual control groups gain regulatory acceptance

For rare diseases, where research often relies on limited animal models and small development teams, the regulatory acceptance of virtual control groups could help streamline early non‑clinical studies while maintaining a strong focus on patient safety.
Insights frInsights from the ERDERA consultancy service surveyom the ERDERA consultancy service survey

Insights from the ERDERA consultancy service survey

Preliminary results point interest across the rare disease research community, while highlighting underrepresentation of some countries and stakeholders

ERDERA's

search form